Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3082417 | 0.90 | HSD17B10 (0.50) | HSD17B10FFAR1HDAC3MAPK1ADRA1A | |
| SCHEMBL3078616 | 0.81 | BCL2L1 (0.47) | SMN1; SMN2OPRD1RXRARXRBRXRG | |
| SCHEMBL655425 | 0.76 | SMN1; SMN2 (0.67) | HSD17B10FFAR1HDAC3MAPK1ADRA1A | |
| SCHEMBL3075832 | 0.73 | TNFRSF1A (0.46) | MAPK1LMNA | |
| SCHEMBL3075837 | 0.73 | TNFRSF1A (0.46) | MAPK1LMNA | |
| SCHEMBL8813092 | 0.71 | SMN1; SMN2 (0.60) | HSD17B10FFAR1HDAC3MAPK1ADRA1A | |
| SCHEMBL414487 | 0.71 | MAPT (0.66) | HSD17B10FFAR1HDAC3MAPK1ADRA1A | |
| SCHEMBL3075680 | 0.71 | LTA4H (0.46) | FFAR1SMN1; SMN2FFAR4 | |
| Sulfuric Acid SCHEMBL8364343 | 0.70 | SMN1; SMN2 (0.58) | HSD17B10FFAR1HDAC3MAPK1ADRA1A | |
| SCHEMBL25293960 | 0.70 | MAPT (0.69) | HSD17B10FFAR1HDAC3MAPK1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261772-A1 | Cycloalkylidene Compounds As Selective Estrogen Receptor Modulators | FANG JING | 2010-10-14 | — | — | US | claimed |
| EP-1891026-B1 | CYCLOALKYLIDENE COMPOUNDS AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | GLAXOSMITHKLINE LLC (US) | 2010-07-14 | — | — | EP | claimed |
| US-7723393-B2 | Cycloalkylidene compounds as selective estrogen receptor modulators | GLAXOSMITHKLINE LLC (US) | 2010-05-25 | — | — | US | claimed |
| US-20080167360-A1 | Cycloalkylidene Compounds as Selective Estrogen Receptor Modulators | SMITHKLINE BEECHAM CORPORATION | 2008-07-10 | — | — | US | claimed |
| EP-1891026-A2 | CYCLOALKYLIDENE COMPOUNDS AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | Smithkline Beecham Corporation (US) | 2008-02-27 | — | — | EP | claimed |
| WO-2006127871-A2 | CYCLOALKYLIDENE COMPOUNDS AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-30 | — | — | WO | claimed |
| US-20100261772-A1 | Cycloalkylidene Compounds As Selective Estrogen Receptor Modulators | FANG JING | 2010-10-14 | — | — | US | disclosed |
| US-20100261772-A1 | Cycloalkylidene Compounds As Selective Estrogen Receptor Modulators | FANG JING | 2010-10-14 | — | — | US | disclosed |
| US-20100261772-A1 | Cycloalkylidene Compounds As Selective Estrogen Receptor Modulators | FANG JING | 2010-10-14 | — | — | US | disclosed |
| EP-1891026-B1 | CYCLOALKYLIDENE COMPOUNDS AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | GLAXOSMITHKLINE LLC (US) | 2010-07-14 | — | — | EP | disclosed |
| US-7723393-B2 | Cycloalkylidene compounds as selective estrogen receptor modulators | GLAXOSMITHKLINE LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723393-B2 | Cycloalkylidene compounds as selective estrogen receptor modulators | GLAXOSMITHKLINE LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723393-B2 | Cycloalkylidene compounds as selective estrogen receptor modulators | GLAXOSMITHKLINE LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-20080167360-A1 | Cycloalkylidene Compounds as Selective Estrogen Receptor Modulators | SMITHKLINE BEECHAM CORPORATION | 2008-07-10 | — | — | US | disclosed |
| US-20080167360-A1 | Cycloalkylidene Compounds as Selective Estrogen Receptor Modulators | SMITHKLINE BEECHAM CORPORATION | 2008-07-10 | — | — | US | disclosed |
| US-20080167360-A1 | Cycloalkylidene Compounds as Selective Estrogen Receptor Modulators | SMITHKLINE BEECHAM CORPORATION | 2008-07-10 | — | — | US | disclosed |
| EP-1891026-A2 | CYCLOALKYLIDENE COMPOUNDS AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | Smithkline Beecham Corporation (US) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006127871-A2 | CYCLOALKYLIDENE COMPOUNDS AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261772-A1 | Cycloalkylidene Compounds As Selective Estrogen Receptor Modulators | GPER1, ESR2, ESRRG | HSD17B10 300/4885FFAR1 127/4885HDAC3 1330/4885 |
| US-20080167360-A1 | Cycloalkylidene Compounds as Selective Estrogen Receptor Modulators | GPER1, ESR2, ESRRG | HSD17B10 300/4885FFAR1 127/4885HDAC3 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.